Clinical trials: sponsored by Peking University
Localized Small Cell Lung Cancer
Adebrelimab Maintenance Therapy for LS-SCLC Post Induction Chemo-Adebrelimab Plus CRT or CRT Alone
Observation and Evaluation of the Efficacy and Safety of Adalimumab Combined with Chemotherapy Followed by Radiotherapy or Radiotherapy Alone as First-Line Treatment for Limited-Stage Small Cell Lung Cancer
- Trial name
- NCT07381543
- Testing
- Adebrelimab Induction Therapy Group, Adebrelimab Maintenance Therapy Group
- Where
- China
- Volunteers
- 76 people
- Sponsor
- Peking University Cancer Hospital & Institute
Pancreatic Cancer Non-resectable
Nimotuzumab Combined With Chemoradiotherapy in the Treatment of Unresectable Locally Advanced or Oligometastatic Pancreatic Cancer
This study is a prospective, single-arm trial, aiming to enroll 30 patients with unresectable locally advanced or oligometastatic pancreatic cancer.
- Trial name
- NCT07386704
- Testing
- Nimotuzumab combined with chemoradiotherapy
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Peking University First Hospital
Smell Dysfunction
The Effectiveness of Steroid Nasal Drops in the Olfactory Cleft Combined With Olfactory Training for Patients With PIOD
This study aims to evaluate the effectiveness of hormone nasal drops in the olfactory cleft combined with olfactory training for treating postinfectious olfactory dysfunction (PIOD).
- Trial name
- PIOD (NCT07386860)
- Testing
- Steroid nasal drops combined with olfactory training
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Peking University Third Hospital
Psoriatic Arthritis, Upadacitinib
Upadacitinib Versus IL-17 Inhibitors in Patients With Psoriatic Arthritis
Psoriatic arthritis (PsA) is a chronic inflammatory disease with heterogeneous musculoskeletal and dermatologic manifestations, leading to significant functional impairment and reduced quality of life.
- Conditions
- Psoriatic Arthritis, Upadacitinib, Interleukin-17 Inhibitors
- Trial name
- UVIPWP (NCT07386717)
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Peking University First Hospital
Rectal Neoplasms Malignant
CAPOX and Bevacizumab With or Without Primary Tumor Radiotherapy and Iparomlimab and Tuvonralimab as First-line Treatment for RAS-Mutant/MSS Metastatic Rectal Cancer
Research objective: To compare the efficacy and safety of Capox + Bev versus Capox + Bev combined with primary site radiotherapy + (Iparomlimab and Tuvonralimab) as the first-line treatment for RAS Mutation/pMMR metastatic rectal…
- Trial name
- NCT07383285
- Testing
- Iparomlimab and Tuvonralimab, Radiotherapy to the primary site, Capecitabine
- Volunteers
- 106 people
- Sponsor
- Peking University Cancer Hospital & Institute
Central Compartment Atopic Disease (CCAD)
Development of A Multi-section Olfactory Cleft Opacity Staging System in Patients With CCAD
This study aims to develop a modified CT scoring system to evaluate the association between olfactory cleft obstruction patterns and olfactory dysfunction in patients with central region atopic disease (CCAD).
- Trial name
- NCT07380945
- Testing
- Computer Tomography
- Where
- China
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Peking University Third Hospital
THA, Prosthesis
A Prospective Multicenter Clinical Study on the Efficacy and Safety of the Zirconia Ceramic Hip Joint Prosthesis System After Its Market Launch
This study adopted a prospective, multi-center, single-group target value trial design to evaluate the safety and efficacy of the hip joint prosthesis system produced by Beijing Anshou Technology Co., Ltd.
- Trial name
- NCT07382050
- Where
- China
- Volunteers
- 290 people
- Sponsor
- Peking University Third Hospital
Psoriasis
A Real-World Study on the Impact of Weight Loss on Treatment Efficacy in Overweight/Obese Patients With Plaque Psoriasis
The goal of this investigator-initiated, real-world, observational study is to investigate the impact of weight loss on treatment efficacy in overweight or obese Chinese patients with moderate-to-severe plaque psoriasis.
- Trial name
- NCT07382388
- Testing
- Weight loss and psoriasis treatment, psoriasis treatment
- Volunteers
- 70 people
- Sponsor
- Peking University Third Hospital
Pelvic Organ Prolapse (POP)
Efficacy and Safety of Laparoscopic Lateral Suspension and Transvaginal Sacrospinous Ligament Fixation in Patients With Pelvic Organ Prolapse
This study is a single-center, non-blinded, non-inferiority randomized controlled trial, planning to recruit 86 patients with Stage III or higher pelvic organ prolapse who are unresponsive to conservative treatment and are…
- Trial name
- NCT06903988
- Testing
- laparoscopic lateral suspension, Transvaginal sacrospinous ligament fixation
- Where
- China
- Volunteers
- 86 people
- Sponsor
- Peking University People's Hospital
B Cell Non-Hodgkin's Lymphoma
A Study of C-CAR039 in Subjects With Relapsed and/or Refractory B Cell Non-Hodgkin's Lymphoma
This is a single-center, open-label study to evaluate the safety and efficacy of C-CAR039 in relapsed and/or refractory B cell Non-Hodgkin's Lymphoma patients.
- Trial name
- NCT05149391
- Testing
- CD19/CD20-directed Chimeric Antigen Receptor T Cells
- Where
- China
- Volunteers
- 3 people
- Sponsor
- Peking University
Prostate Cancer
The Development and Validation of MRI-AI-based Predictive Models for csPCa
This study retrospectively included patients who underwent prostate magnetic resonance imaging (MRI) and subsequent ultrasound-guided prostate biopsy at Peking University First Hospital from January 2019 to December 2023, and…
- Trial name
- NCT06842264
- Where
- China
- Volunteers
- 3,000 people
- Sponsor
- Peking University First Hospital
Non-Small Cell Lung Cancer, ALK
Iruplinalkib in ALK-Positive Advanced Lung Adenocarcinoma After Lorlatinib
This observational study aims to evaluate the real-world effectiveness and safety of iruplinalkib in patients with advanced ALK-positive lung adenocarcinoma who have progressed on or are intolerant to prior lorlatinib therapy.
- Conditions
- Non-Small Cell Lung Cancer, ALK, Iruplinalkib, Lorlatinib
- Trial name
- SAILOR (NCT07374614)
- Testing
- Iruplinalkib tablets
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Peking University Shenzhen Hospital
Patients With Solid Tumors
Traditional Chinese Medicine Hand-Foot Soak for Chemotherapy-Induced Peripheral Neuropathy and Hand-Foot Syndrome
Systemic therapies, including chemotherapy, targeted therapy, and immunotherapy, are cornerstones of modern oncology and have significantly extended patient survival.
- Trial name
- NCT07375446
- Testing
- Traditional Chinese Medicine
- Volunteers
- 300 people
- Sponsor
- Peking University Third Hospital
Intrahepatic Cholangiocarcinoma (Icc), Perihilar Cholangiocarcinoma
Perioperative Treatment of High-risk Resectable CCA With HAIC Plus A+T: Neobrave CCA
Among resectable biliary tract cancers (BTC) patients, surgery has historically been the standard treatment, but even with curative surgery, the cure rates remain relatively low, with most patients relapsing in the short term and…
- Trial name
- NCT06739252
- Testing
- Gemcitabine Oxaliplatin and 5FU
- Where
- China
- Volunteers
- 1 people
- Sponsor
- Peking University
Hemodynamically Significant Patent Ductus Arteriosus
Research on the Individualized Treatment Strategy for Extremely Preterm Infants With hsPDA Based on Biomarkers and Targeted Delivery Systems
This project aims to address the need for individualized precision therapy for hemodynamically significant patent ductus arteriosus (hsPDA) in extremely preterm infants by integrating clinical biomarker screening with the design…
- Trial name
- BTDS-IT-hsPDA- (NCT07374146)
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Peking University Third Hospital
Radiation Therapy, Metastatic Renal Cancer
SABR Combined With Targeted Therapy and Anti-PD-1 for Recurrent or Metastatic Renal Cancer
Renal cancer ranks seventh in incidence among men and sixth among women in the Beijing area, with Peking University First Hospital treating over 1,000 kidney cancer patients annually.
- Conditions
- Radiation Therapy, Metastatic Renal Cancer, Recurrent Renal Cell Cancer
- Trial name
- COSTAR (NCT06583070)
- Testing
- Radiation therapy, Targeted and immunotherapy
- Where
- 2 sites in China
- Volunteers
- 300 people
- Sponsor
- Peking University First Hospital
Cerebral Small Vessel Disease, Postoperative Cognitive Function
VR Training to Improve Postoperative Cognitive Function in Elderly Patients With Cerebral Small Vessel Disease Undergoing Non-Cardiac Surgery
This clinical study aims to investigate whether virtual reality (VR)-based cognitive training can help improve postoperative cognitive function in elderly non-cardiac surgery patients with pre-existing cerebral small vessel…
- Trial name
- NCT07370844
- Testing
- Virtual reality cognitive function training, Virtual scene intervention
- Where
- 3 sites in China
- Volunteers
- 240 people
- Sponsor
- Peking University Third Hospital
Lung Cancers
A Study on the Improvement of Postoperative Symptoms and Survival Benefits of Modified Bufei Decoction in Elderly Patients With Lung Cancer Undergoing Radical Surgery
This is a randomized double-blind placebo-controlled phase II clinical study that included patients with symptoms such as cough, shortness of breath, and fatigue after lung cancer resection surgery.
- Trial name
- NCT06674252
- Testing
- Jiawei Bufei Tang granules
- Where
- 2 sites in China
- Volunteers
- 174 people
- Sponsor
- Peking University Cancer Hospital & Institute
Rectal Cancer, Gut Microbiomes
Autologous Probiotics in Patients With Defunctioning Ileostomy Following LAR for Rectal Cancer
Rectal cancer patients who received low anterior resection combined with ileostomy may effectively reduce the probability of anastomotic leakage after surgery.
- Conditions
- Rectal Cancer, Gut Microbiomes, Autologous Probiotic Transplantation, Defunctioning Ileostomy
- Trial name
- NCT07366047
- Testing
- Autologous Probiotics
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Peking University Cancer Hospital & Institute
Hepatocellular Carcinoma, Portal Vein Thrombosis
HAIC Combine With Lenvatinib and PD-1 Inhibitors for Advanced HCC With PVTT
The purpose of this study is to evaluate the safety and efficacy of hepatic arterial infusion chemotherapy combined with Lenvatinib and PD-1 inhibitors compared to Lenvatinib plus PD-1 inhibitors for advanced hepatocellular…
- Trial name
- NCT05166239
- Testing
- HAIC, Lenvatinib 1, PD-1 Inhibitors
- Where
- China
- Volunteers
- 66 people
- Sponsor
- Peking University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.